 Patients treated at the maximum tolerated dose undergo fludeoxyglucose F 18 positron emission tomography at baseline and on day 28. These patients also undergo tumor tissue and blood sample collection at baseline and periodically during study for correlative laboratory studies. Samples are analyzed for tyrosine phosphorylated or total MAP-K, EGFR, AKT, and other potential biomarkers of activityresponse and for levels of genes transcriptionally activated e.g., BCL-2, GLI, BFL-1A1, 4-1BB, PTC1 by immunofluorescence, IHC, and quantitative-PCR. 